Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibit development of secondary hyperalgesia in man by a peripheral action.

Due to the recent discovery of peripheral N-methyl-D-aspartate (NMDA) (and other glutamate) receptors in animal studies, the NMDA receptor antagonist, ketamine (0.83 mg/ml, 6 ml) or saline was injected s.c. preinjury in 10 healthy volunteers, to study the effect on burn-induced primary and secondary hyperalgesia. On the saline treated leg, all subjects developed primary hyperalgesia and secondary hyperalgesia. On the contralateral leg treated with ketamine, there was a significant reduction of primary hyperalgesia and an inhibition of development of secondary hyperalgesia. In an experimental day 2, lidocaine temporarily blocked the development of primary and secondary hyperalgesia. When saline was injected in the contralateral leg treated with ketamine 1 week previously (n = 6), no zone of secondary hyperalgesia was developed. In contrast, subjects (n = 3) treated with ketamine 2 weeks before, reported development of secondary hyperalgesia following saline, a preliminary indication of a long-lasting peripheral action of ketamine.
AuthorsT Warncke, E Jørum, A Stubhaug
JournalNeuroscience letters (Neurosci Lett) Vol. 227 Issue 1 Pg. 1-4 (May 09 1997) ISSN: 0304-3940 [Print] Ireland
PMID9178844 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Excitatory Amino Acid Antagonists
  • Receptors, N-Methyl-D-Aspartate
  • Ketamine
  • Adult
  • Double-Blind Method
  • Excitatory Amino Acid Antagonists (therapeutic use)
  • Humans
  • Hyperalgesia (prevention & control)
  • Ketamine (therapeutic use)
  • Male
  • Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
  • Sensory Thresholds (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: